Beam Therapeutics reports initial Phase 1/2 data for BEAM-301 in glycogen storage disease type Ia trial

By Public Technologies
  • Beam Therapeutics flagged initial Phase 1/2 results for BEAM-301 in glycogen storage disease type Ia for presentation at ESGCT.
  • Data showed signs of restored patients’ ability to maintain glucose levels following a single dose, with stronger effects at higher dosing.
  • Patients reduced reliance on frequent starch dosing, supporting early clinical proof of concept for mutation-targeted genetic correction.
  • Safety profile looked consistent with lipid nanoparticle therapies, with manageable infusion reactions; no dose-limiting toxicities or deaths were reported.
  • An investor webcast is scheduled for Oct. 27, 2026, ahead of the Oct. 28 poster presentation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130700PRIMZONEFULLFEED9844240) on October 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.